Core Viewpoint - The demand for anti-wrinkle and firming skincare products in China is rapidly increasing, with the retail market expected to reach 64.027 billion yuan in 2024, reflecting a year-on-year growth of 21.50%. Consumers are shifting from a focus on single efficacy to multi-functional products that offer benefits such as anti-free radical and skin barrier repair, marking a transition from "ingredient stacking" to "mechanism-driven" innovations in the industry [1][16]. Overview - Anti-wrinkle and firming skincare products aim to improve skin wrinkles and enhance elasticity and firmness. Their mechanisms include supplementing or stimulating the synthesis of collagen and elastin, improving skin moisture content and barrier function, inhibiting the activity of enzymes that damage skin structure, and providing antioxidant and anti-inflammatory effects to mitigate skin aging [2][5]. Development History - The domestic skincare market was in its infancy before the 1990s, with limited demand for anti-wrinkle products. The introduction of these products began in the 1990s, primarily through imported brands. Post-2010, the market experienced rapid growth due to increased consumer awareness and economic development, leading to the rise of domestic brands that began to compete effectively with multinational companies [5][6]. Market Policies - The Chinese government has implemented a series of policies to enhance the development of the cosmetics industry, including regulations on production quality management, adverse reaction monitoring, and electronic registration. These policies aim to promote standardization and high-quality development in the anti-wrinkle and firming skincare sector [10][11]. Industry Chain - The upstream of the anti-wrinkle and firming skincare industry includes suppliers of active ingredients like hyaluronic acid and peptides, as well as suppliers of moisturizing agents and packaging materials. The downstream consists of various sales channels, including department stores, supermarkets, specialty stores, beauty salons, and e-commerce platforms [13][15]. Consumer Insights - The consumer base for anti-wrinkle and firming products is predominantly female, accounting for over 85%, while the male anti-aging market is growing at a rate of 30%. The core consumer group is aged 26-35, focusing on preventive anti-aging and multifunctional products. Safety is the primary concern for 94.93% of consumers, significantly impacting repurchase rates and brand trust [15][16]. Competitive Landscape - The market is becoming increasingly competitive, with international brands like Estée Lauder, L'Oréal, Procter & Gamble, and Shiseido dominating the mid-to-high-end segments. Domestic brands such as Proya, Chando, and Marubi are gaining significant market share due to their understanding of local consumer preferences and competitive pricing [19][22]. Future Trends - The future demand for anti-aging products will focus on multi-functional benefits, including anti-wrinkle, anti-free radical, and skin barrier repair. There is a growing emphasis on emotional value, with over half of female consumers willing to purchase products that offer additional emotional satisfaction, prompting brands to enhance their offerings through packaging design and brand storytelling [27][29].

Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].

证券之星消息，8月4日化妆品板块较上一交易日上涨0.58%，丸美生物领涨。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。化妆品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603983 | 丸美生物 | 39.96 | 3.28% | 3.09万 | | 1.22亿 | | 300886 | 华业看料 | 29.06 | 2.50% | 2.57万 | 7403.36万 | | | 300740 | 水羊股份 | 17.22 | 2.38% | 16.33万 | | 2.78亿 | | 300132 | 青松股份 | 6.06 | 1.34% | 12.64万 | 7571.49万 | | | 002243 | 力合科创 | 8.25 | 1.23% | 11.75万 | 9597.90万 | | | 300856 | 科思股份 | 15.10 | 0.80% | 3.11万 | 4667.26万 | ...

Investment Rating - The report suggests a positive outlook for domestic brands and a recovery for international beauty brands in the Chinese market, indicating potential investment opportunities in the cosmetics and medical beauty sectors [2][3]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 3.3% from July 25 to August 1, 2025, while the Shenwan Cosmetics Index fell by 2.6% [3][4]. - Domestic brands showed strong growth during the off-season, with notable increases such as Han Shu up 58%, Proya up 23%, Marubi up 72%, and Kefu Mei up 28%, indicating resilience in the market [7][17]. - International beauty brands, represented by L'Oréal, are recovering in the Chinese market, with a 3% growth in Q2 2025, supported by promotional events like the 618 shopping festival [7][24]. - The report highlights the success of Lin Qingxuan, a high-end domestic skincare brand, which saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, showcasing the potential of domestic brands [13][14]. Summary by Sections Industry Performance - The beauty and medical aesthetics sector has shown weaker performance compared to the overall market, with specific indices declining [3][4]. - The report notes that the cosmetics market is transitioning from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of cosmetics sales in 2024, up from 22% in 2016 [9][30]. Key Company Highlights - L'Oréal's sales in China for H1 2025 reached approximately 186.19 billion yuan, with a 3% year-on-year increase, indicating a recovery in the Chinese market [24]. - Procter & Gamble reported a record net sales of approximately 604.95 billion yuan for the 2025 fiscal year, with the beauty segment achieving a net sales of approximately 107.66 billion yuan, reflecting a 2% growth [25]. - Lin Qingxuan's product matrix includes 188 SKUs, with a focus on high-quality natural ingredients, and it has established a strong supply chain and distribution network [14][16]. Market Trends - The report emphasizes the growing market for high-end skincare products, with the market size expected to increase from 749 billion yuan in 2019 to 1,144 billion yuan by 2024, indicating a compound annual growth rate (CAGR) of 13.8% [14][15]. - The domestic brands are gaining market share, with the top ten brands in the skincare market now evenly split between domestic and international brands, reflecting a shift in consumer preferences [30][31].

| 代码 | 简称 | 今日涨跌 | 今日换手 | 5日均线 | 10日均线 | 5日较10日均线 | 最新价 | 较10日均线乖 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | （%） | 率（%） | （元） | （元） | 距离（%） | （元） | 离率（%） | | 002052 | 同洲 | -0.77 | 2.45 | 10.71 | 10.85 | -1.25 | 10.32 | -4.85 | | | 电子 | | | | | | | | | 002989 | 中天 | -0.77 | 2.14 | 32.36 | 32.71 | -1.07 | 31.12 | -4.87 | | | 精装 | | | | | | | | | 603983 | 丸美 生物 | -2.64 | 0.70 | 39.79 | 40.17 | -0.93 | 38.69 | -3.68 | | | 格科 | | | | | | | | | 688728 | 微 | 0.46 | 0.48 | 15.71 | 15.82 | -0.68 ...

Market Overview - The Shanghai Composite Index is at 3555.41 points, with a decline of 0.50% [1] - The total trading volume of A-shares is 128.87 billion yuan [1] Technical Analysis - A total of 64 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Tongzhou Electronics: -1.29% - Marubi Biological: -0.95% - GeKao Micro: -0.69% [1] Individual Stock Performance - Key stock performances include: - Tongzhou Electronics (002052): Today's change -1.15%, 5-day MA at 10.70 yuan, 10-day MA at 10.84 yuan, with a distance of -1.29% [1] - Marubi Biological (603983): Today's change -2.84%, 5-day MA at 39.78 yuan, 10-day MA at 40.16 yuan, with a distance of -0.95% [1] - GeKao Micro (688728): Today's change 0.33%, 5-day MA at 15.71 yuan, 10-day MA at 15.82 yuan, with a distance of -0.69% [1] - Other notable stocks include: - Huatai Securities (601059): Today's change -0.86%, 5-day MA at 16.73 yuan, 10-day MA at 16.84 yuan, with a distance of -0.66% [1] - Jiabao (600622): Today's change -1.01%, 5-day MA at 3.08 yuan, 10-day MA at 3.10 yuan, with a distance of -0.64% [1] Additional Stock Movements - Other stocks with notable movements include: - Laka Laka (300773): Today's change -4.02%, 5-day MA at 27.62 yuan, 10-day MA at 27.73 yuan, with a distance of -0.39% [2] - Yongtai Technology (002326): Today's change 4.09%, 5-day MA at 13.25 yuan, 10-day MA at 13.29 yuan, with a distance of -0.32% [2] - Qijing (603677): Today's change -0.46%, 5-day MA at 19.91 yuan, 10-day MA at 19.96 yuan, with a distance of -0.25% [2]

Group 1 - The Shanghai Composite Index is at 3575.26 points with a slight increase of 0.06% and total A-share trading volume is 735.89 billion yuan [1] - A total of 55 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include Tongzhou Electronics at -1.19%, Marubi Biological at -0.82%, and Everbright Jiabao at -0.61% [1] Group 2 - Additional stocks showing a downward trend in their moving averages include Ge Ke at -0.61%, Hisense at -0.57%, and Beichen at -0.55% [1] - Other companies with notable moving average crossovers include Wan Shi at -0.53%, Baoling at -0.50%, and Zhejiang University at -0.49% [1] - The report also highlights stocks like PAI Neng and ST Zhong with minor declines in their moving averages, indicating a broader trend in the market [1]

Group 1 - The stock price of Marubi Biotechnology closed at 40.04 yuan on July 30, 2025, down 0.15% from the previous trading day, with a trading volume of 0.87 billion yuan and a turnover rate of 0.54% [1] - Marubi Biotechnology operates in the beauty care industry, focusing on anti-aging eye products, with main brands "Marubi" and makeup brand "PL Love Fire" [1] - The company is transitioning towards the biotechnology sector by restructuring its collagen research and plans to expand into the medical beauty and healthcare industries [1] Group 2 - Marubi Biotechnology has commenced construction of a Class III medical device pilot base in Zhuhai International Health Port, focusing on the research and industrialization of recombinant collagen [1] - The company has set a ten-year research plan aiming to obtain a registration certificate for injectable recombinant collagen Class III medical devices by 2026 [1] - In 2024, the company plans to invest 73.54 million yuan in research and development, employing 94 research personnel [1] Group 3 - On July 30, 2025, the net outflow of main funds for Marubi Biotechnology was 12.24 million yuan, accounting for 0.08% of the circulating market value [2]

智通财经记者 | 朱咏玲 智通财经编辑 | 楼婍沁 丸美生物最近在珠海国际健康港园区内投建的Ⅲ类医疗器械中试基地正式动工。据品牌方，该项目将聚焦医美领域前沿的重组胶原 蛋白研发和产业化。 智通财经向丸美生物询问该项目的更多信息，截至发稿未获回复。 结合丸美生物近些年的种种举措来看，这一老牌美妆企业如今有了更大的追求，要以重组胶原蛋白为切入点深入到上游的科研端， 并将其应用领域从生活美容延伸到医疗美容，由化妆品公司升级为生物科技公司。 除了投建Ⅲ类医疗器械中试基地外，近两年丸美生物在这一方向上的举措还包括将公司名从"丸美股份"变更为"丸美生物"、投资医 用生物材料公司等。 这背后的考量不难理解。 化妆品行业经营管理专家、新质美妆发起人白云虎对智通财经表示，丸美押注重组胶原蛋白等医美赛道，是其品牌早期定位侧重在 抗衰老层面的延续。很长时间以来，丸美都聚焦以眼部护理为核心的抗衰老细分领域，早在电视营销时代，丸美就凭借"弹弹弹，弹 走鱼尾纹"的广告语形成了这一品牌心智。而重组胶原蛋白的主打功效之一正是抗皱和紧致皮肤。 且重组胶原蛋白近些年热度颇高，不少时下热销的国货护肤品都将其作为核心成分，相关市场教育相对成熟。企业 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting the strong performance of domestic brands amid stricter regulations [1]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 5.4% from July 18 to July 25, 2025, surpassing the Shenwan A Index by 1.2 percentage points [5][6]. - Stricter advertising regulations are expected to benefit leading domestic brands, as new rules will increase operational barriers and allow market share to concentrate among top players [11]. - The report emphasizes the importance of new product launches as brands prepare for the competitive landscape in the second half of 2025 [11]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 3.4%, outperforming the Shenwan A Index by 1.2 percentage points, while the Shenwan Personal Care Index rose by 7.7%, exceeding the Shenwan A Index by 5.5 percentage points [5][6]. Key Company Highlights - Lin Qingxuan, a high-end domestic skincare brand, saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [17]. - The company has a diverse product matrix with 188 SKUs, a robust supply chain with an annual production capacity of 40 million units, and a comprehensive OMO channel strategy [19]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with e-commerce sales expected to account for 47% of total cosmetics sales by 2024, up from 22% in 2016 [13]. - The domestic market is witnessing a rise in local brands, with significant market share gains, particularly in the skincare segment [37]. Investment Recommendations - The report recommends several companies based on their market positioning and growth potential, including Up Beauty, Proya, and Marubi, while suggesting to pay attention to Shanghai Jahwa, Betaini, and Huaxi Biological [5].